☆ 4.6 Article

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

FRONTIERS IN ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

How I manage infection risk and prevention in patients with lymphoid cancer

Nancy Law et al.

Summary: This article highlights the fundamental issues in treating infections in lymphoid cancer patients, including risk factors, screening, and antimicrobial prophylaxis recommendations. It provides a treatment approach based on evidence-based data and experience. The goal is to assist institutions and healthcare providers in developing their own strategies for preventing and treating infections in lymphoid cancer patients.

BLOOD (2022)

添加到收藏夹

Article Hematology

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have impaired antibody response to COVID-19 vaccination. A third dose of the vaccine can improve the antibody response in some CLL patients. Patients on active treatment and those recently treated with anti-CD20 therapy have lower antibody response rates.

BLOOD (2022)

添加到收藏夹

Article Hematology

COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity

Yandong Shen et al.

Summary: Chronic lymphocytic leukaemia (CLL) and monoclonal B-cell lymphocytosis (MBL) patients have poor immune response to COVID-19 vaccines, with most of them failing to produce sufficient antibody levels. The patients' treatment status and reduced immune function are associated with vaccine immunization failure.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Review Medicine, Research & Experimental

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

Mitra Rezaei et al.

Summary: This review investigates the role of the BTK pathway in the pathogenesis of COVID-19 and the potential effects of its inhibition in treating the disease. Some data suggest that using BTK inhibitors may be beneficial for treating COVID-19.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2022)

添加到收藏夹

Review Medicine, Research & Experimental

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Jingjing Zhang et al.

Summary: Early immune responses to SARS-CoV-2 are mainly mediated by IgM and IgA antibodies, which are crucial for neutralizing the virus at mucosal sites. While most authorized neutralizing antibodies are IgG antibodies, the potential of IgM, IgA, and bispecific antibodies (bsAbs) for therapeutic and prophylactic purposes against SARS-CoV-2 infection is discussed. The challenges and future directions in vaccine design and antibody-based therapeutics are also highlighted.

MABS (2022)

添加到收藏夹

Article Immunology

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

Steven E. Coutre et al.

Summary: Ibrutinib did not improve the proportion of hospitalized patients with severe COVID-19 who were alive and without respiratory failure through day 28. Ibrutinib had a manageable safety profile, similar to placebo.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Virology

The outcome of COVID-19 in patients with hematological malignancy

Tugce N. Yigenoglu et al.

Summary: This study shows that patients with hematological malignancy have a higher risk of COVID-19-related severe events compared to those without cancer, with higher rates of ICU admission, mechanical ventilation support, and death. It confirms the heightened vulnerability of patients with hematological malignancy during the current pandemic.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Hematology

Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic

Petra Langerbeins et al.

Summary: The novel coronavirus, SARS-CoV-2, was first identified in Wuhan, China in December 2019, leading to a global pandemic. Cancer patients, especially those with chronic lymphocytic leukemia (CLL), are at higher risk for severe SARS-CoV-2 infections due to their impaired immune systems. Treatment initiation can further increase the risk of severe infections for CLL patients.

ACTA HAEMATOLOGICA (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

Carlos Cruz-Teran et al.

Summary: The article discusses the global efforts to combat the COVID-19 pandemic with potent neutralizing mAbs and highlights the challenges faced by current antiviral mAbs. It also presents evidence supporting inhaled delivery of antiviral mAbs as an early intervention against COVID-19.

ADVANCED DRUG DELIVERY REVIEWS (2021)

添加到收藏夹

Article Oncology

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou et al.

Summary: Patients with CLL are more susceptible to the impact of COVID-19, with age, CLL-directed treatment, and cardiac failure being significant risk factors for outcomes. Untreated patients have a better chance of survival, and age, cardiac failure, and CLL-directed treatment are significant risk factors for OS.

LEUKEMIA (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Benjamin Gaborit et al.

Summary: Early inhibition of SARS-CoV-2 entry and replication using polyclonal neutralizing antibodies shows promising therapeutic potential by providing immediate immunity and blocking viral infection in ACE-2-positive human cells. The study aims to determine the safety, optimal dose, and clinical benefits of XAV-19 in patients with COVID-19-induced moderate pneumonia, with the goal of potentially introducing it as a new therapeutic option in combination with antiviral and immunotherapies.

TRIALS (2021)

添加到收藏夹

Review Hematology

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs et al.

Summary: Tyrosine kinase inhibitors are being explored for use in the treatment of different stages of COVID-19 and other hematologic malignancies, although most studies are done in vitro and may not apply to a wider population. Many in vivo effects reported are based on artificial animal models or symptomatic patients with hematologic malignancies.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Oncology

Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

Maria Stefania Infante et al.

Summary: This study analyzed infectious complications in patients with lymphoproliferative diseases treated with targeted therapies. Severe infections occurred in 23% of patients, predominantly bacterial in nature, with a small percentage attributed to invasive fungal infections. Risk factors for severe infection included severe lymphopenia, combined targeted treatment, and previous rituximab usage. Infection-related mortality was 6%, and antimicrobial prophylaxis should be considered in high-risk cases.

CANCER MEDICINE (2021)

添加到收藏夹

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Francesco Passamonti et al.

Summary: The study found a low rate of seroconversion in patients with hematological malignancies, possibly due to treatment-mediated immune dysfunction.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry et al.

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Oncology

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Hematology

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

Martin Dreyling et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

添加到收藏夹

Article Hematology

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

David J. Straus et al.

BLOOD (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Hematology

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Steven P. Treon et al.

BLOOD (2020)

添加到收藏夹

Letter Biophysics

COVID-19 outcomes in patients with hematologic disease

Florent Malard et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹

Letter Hematology

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Santiago Thibaud et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Letter Hematology

Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies

Fernando Martin-Moro et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P Sharman et al.

LANCET (2020)

添加到收藏夹

Article Hematology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato et al.

BLOOD (2020)

添加到收藏夹

Letter Hematology

COVID-19 in patients with hematological malignancies: A retrospective case series

Maria-Stefania Infante et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)

添加到收藏夹

Article Oncology

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfo et al.

LEUKEMIA (2020)

添加到收藏夹

Article Oncology

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al-Sawaf et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Oncology

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Ian W. Flinn et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Letter Oncology

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry A. Rogers et al.

LEUKEMIA (2019)

添加到收藏夹

Review Oncology

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology

Pier Luigi Zinzani et al.

LEUKEMIA RESEARCH (2019)

添加到收藏夹

Article Medicine, General & Internal

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

T. D. Shanafelt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Hematology

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies

Benjamin W. Teh et al.

BLOOD REVIEWS (2018)

添加到收藏夹

Review Infectious Diseases

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

L. Drgona et al.

CLINICAL MICROBIOLOGY AND INFECTION (2018)

添加到收藏夹

Article Oncology

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Wolfgang Hiddemann et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. M. Connors et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

F. Morschhauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Letter Hematology

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Gilles Salles et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Letter Hematology

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Gilles Salles et al.

HAEMATOLOGICA (2017)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls

J. Moreira et al.

LEUKEMIA (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.